tetano
Editor, Senior Moderator
Mol Pharm. 2015 Jan 20. [Epub ahead of print]
[h=1]Inhalable dry powder formulations of siRNA and pH responsive peptides with antiviral activity against H1N1 influenza virus.[/h] Liang W, Chow MY, Lau PN, Zhou QT, Kwok PC, Leung GP, Mason AJ, Chan HK, Poon LL, Lam JK.
[h=3]Abstract[/h] Pulmonary delivery of siRNA has considerable therapeutic potential for treating viral respiratory infectious diseases including influenza. By introducing siRNA that targets the conserved region of viral genes encoding nucleocapsid protein (NP), viral mRNAs can be degraded and viral replication can be inhibited in mammalian cells. To enable siRNA to be used as an antiviral agent, the nucleic acid delivery barrier must be overcome. Effective local delivery of siRNA to lung tissues is required to reduce therapeutic dose and minimize systemic adverse effects. To develop a formulation suited for clinical application, complexes of pH responsive peptides, containing either histidine or 2,3-diaminopropionic acid (Dap), and siRNA were prepared into dry powders by spray drying with mannitol used as bulking agent. The spray-dried (SD) powders were characterised and found to be suitable for inhalation with good stability; preserving the integrity of the siRNA as well as the biological and antiviral activities. The formulations mediated highly effective in vitro delivery of antiviral siRNA into mammalian lung epithelial cells, leading to significant inhibition of viral replication when the transfected cells were subsequently challenged with H1N1 influenza virus. SD siRNA powders containing pH responsive peptides are a promising inhalable formulation to deliver antiviral siRNA against influenza and are readily adapted for the treatment of other respiratory diseases.
PMID: 25599953 [PubMed - as supplied by publisher]
[h=1]Inhalable dry powder formulations of siRNA and pH responsive peptides with antiviral activity against H1N1 influenza virus.[/h] Liang W, Chow MY, Lau PN, Zhou QT, Kwok PC, Leung GP, Mason AJ, Chan HK, Poon LL, Lam JK.
[h=3]Abstract[/h] Pulmonary delivery of siRNA has considerable therapeutic potential for treating viral respiratory infectious diseases including influenza. By introducing siRNA that targets the conserved region of viral genes encoding nucleocapsid protein (NP), viral mRNAs can be degraded and viral replication can be inhibited in mammalian cells. To enable siRNA to be used as an antiviral agent, the nucleic acid delivery barrier must be overcome. Effective local delivery of siRNA to lung tissues is required to reduce therapeutic dose and minimize systemic adverse effects. To develop a formulation suited for clinical application, complexes of pH responsive peptides, containing either histidine or 2,3-diaminopropionic acid (Dap), and siRNA were prepared into dry powders by spray drying with mannitol used as bulking agent. The spray-dried (SD) powders were characterised and found to be suitable for inhalation with good stability; preserving the integrity of the siRNA as well as the biological and antiviral activities. The formulations mediated highly effective in vitro delivery of antiviral siRNA into mammalian lung epithelial cells, leading to significant inhibition of viral replication when the transfected cells were subsequently challenged with H1N1 influenza virus. SD siRNA powders containing pH responsive peptides are a promising inhalable formulation to deliver antiviral siRNA against influenza and are readily adapted for the treatment of other respiratory diseases.
PMID: 25599953 [PubMed - as supplied by publisher]